Literature DB >> 30854491

Predictive markers in gastric cancer immunotherapy treatment-are we there yet?

Rutika Mehta1, Khaldoun Almhanna2.   

Abstract

Entities:  

Year:  2019        PMID: 30854491      PMCID: PMC6378244          DOI: 10.21037/tgh.2019.01.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


× No keyword cloud information.
  12 in total

1.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

2.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Authors:  Charles S Fuchs; Toshihiko Doi; Raymond W Jang; Kei Muro; Taroh Satoh; Manuela Machado; Weijing Sun; Shadia I Jalal; Manish A Shah; Jean-Phillipe Metges; Marcelo Garrido; Talia Golan; Mario Mandala; Zev A Wainberg; Daniel V Catenacci; Atsushi Ohtsu; Kohei Shitara; Ravit Geva; Jonathan Bleeker; Andrew H Ko; Geoffrey Ku; Philip Philip; Peter C Enzinger; Yung-Jue Bang; Diane Levitan; Jiangdian Wang; Minori Rosales; Rita P Dalal; Harry H Yoon
Journal:  JAMA Oncol       Date:  2018-05-10       Impact factor: 31.777

3.  Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

Authors:  Toshihiko Doi; Sarina A Piha-Paul; Shadia I Jalal; Sanatan Saraf; Jared Lunceford; Minori Koshiji; Jaafar Bennouna
Journal:  J Clin Oncol       Date:  2017-11-08       Impact factor: 44.544

4.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

5.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

6.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

7.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.

Authors:  Justin I Odegaard; John J Vincent; Stefanie Mortimer; James V Vowles; Bryan C Ulrich; Kimberly C Banks; Stephen R Fairclough; Oliver A Zill; Marcin Sikora; Reza Mokhtari; Diana Abdueva; Rebecca J Nagy; Christine E Lee; Lesli A Kiedrowski; Cloud P Paweletz; Helmy Eltoukhy; Richard B Lanman; Darya I Chudova; AmirAli Talasaz
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

8.  CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

Authors:  Yelena Y Janjigian; Johanna Bendell; Emiliano Calvo; Joseph W Kim; Paolo A Ascierto; Padmanee Sharma; Patrick A Ott; Katriina Peltola; Dirk Jaeger; Jeffry Evans; Filippo de Braud; Ian Chau; Christopher T Harbison; Cecile Dorange; Marina Tschaika; Dung T Le
Journal:  J Clin Oncol       Date:  2018-08-15       Impact factor: 44.544

9.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.

Authors:  Zipei Feng; Sachin Puri; Tarsem Moudgil; William Wood; Clifford C Hoyt; Chichung Wang; Walter J Urba; Brendan D Curti; Carlo B Bifulco; Bernard A Fox
Journal:  J Immunother Cancer       Date:  2015-10-20       Impact factor: 13.751

10.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.